Fractionated high-dose cyclophosphamide for advanced pediatric solid tumors

Area of Science:

• Pediatric Oncology
• Pharmacology
• Cancer Treatment

Background:

• Advanced solid tumors in children pose significant treatment challenges.
• High-dose chemotherapy regimens are often explored to improve outcomes.
• Cyclophosphamide (CPA) is a widely used chemotherapeutic agent.

Purpose of the Study:

• To evaluate the safety and tolerability of high-dose cyclophosphamide (CPA) at 7 g/m2 in pediatric patients.
• To assess the toxicities associated with a specific dosing schedule of CPA (four fractions over 8 hours).
• To determine the feasibility of outpatient management for this high-dose CPA regimen.

Main Methods:

• Twenty pediatric patients with advanced solid tumors received 24 courses of CPA at 7 g/m2.
• CPA was administered in four divided infusions over 8 hours, with MESNA for uroprotection.
• Supportive care included G-CSF, ciprofloxacin, and co-trimoxazole; most patients were managed as outpatients.

Main Results:

• Severe but transient myelosuppression was observed, with median recovery times of 17 days for neutrophils and 19 days for platelets.
• Fever occurred in 13 courses, necessitating hospitalization in some cases.
• No instances of cardiomyopathy or hemorrhagic cystitis were reported, and 46% of courses were managed outpatient.

Conclusions:

• High-dose cyclophosphamide (CPA) at 7 g/m2 is well-tolerated in pediatric patients with advanced malignancies.
• The regimen is associated with manageable toxicities, including mild extramedullary effects.
• This CPA dosing strategy warrants consideration for earlier phases of antineoplastic therapy in children.